Enliven Therapeutics, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Financial statements are unaudited. Enliven is a clinical-stage oncology company with no approved products and no product revenue. The February 2023 merger with Imara was accounted for as a reverse recapitalization, with Former Enliven treated as the accounting acquirer.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $19.6M | $7.8M | $46.7M | $22.8M |
| General and administrative expense | $4.6M | $3.1M | $14.1M | $5.8M |
| Total operating expenses | $24.2M | $10.9M | $60.8M | $28.6M |
| Operating loss | $(24.2)M | $(10.9)M | $(60.8)M | $(28.6)M |
| Interest income | $3.5M | $0.4M | $8.6M | $0.5M |
| Net loss | $(20.8)M | $(10.6)M | $(52.2)M | $(28.1)M |
| Basic and diluted loss per share | $(0.51) | $(3.27) | $(1.55) | $(9.15) |
At September 30, 2023, cash and cash equivalents were $73.8M and marketable securities were $189.6M; together, approximately $263.5M. Current assets were $268.6M versus current liabilities of $12.1M. Total liabilities were $12.3M, including lease obligations; the company reported no debt outstanding. Accumulated deficit was $135.1M. No meaningful operating margin is available because the company had no revenue.
For the first nine months of 2023, operating cash use was $48.8M, investing cash use was $187.1M—primarily purchases of marketable securities—and financing provided $234.2M. Cash, cash equivalents and restricted cash decreased by $1.7M to $73.9M; marketable securities are additional liquidity.
Changes and notable items
- Q3 R&D expense increased $11.8M year over year, mainly from clinical-trial costs ($6.2M) and contract manufacturing ($3.7M), along with higher employee-related costs.
- Nine-month R&D expense increased $23.8M, primarily reflecting higher clinical-trial and manufacturing costs, salaries and stock-based compensation.
- Q3 G&A expense rose $1.5M. Nine-month G&A rose $8.3M, including higher stock-based compensation, professional services and merger-related option-vesting expense; the comparison also reflects a $1.7M IPO-cost write-off in 2022.
- Net losses grew, but higher interest income—attributed to higher rates and investment balances—partly offset operating losses.
- The February 2023 merger and associated financing included $164.5M of gross proceeds from the pre-merger common-stock financing. The merger converted preferred stock into common stock and materially increased shares outstanding. Common shares outstanding were 41.2M at September 30.
- Stock-based compensation was $9.9M for the nine months, versus $2.5M in the prior-year period. Unrecognized compensation cost on unvested options was $38.2M.
Outlook, risks and contingencies
- Management expects operating losses and negative operating cash flows to continue, with expenses rising as programs advance. It said available cash, cash equivalents and marketable securities should fund planned operations for at least 12 months from the filing date. A separate risk-factor disclosure says funding is expected into early 2026; these runway statements use different formulations and should be reconciled by investors.
- The company has no approved products and does not expect meaningful revenue unless and until a candidate is approved and commercialized. It expects substantial additional capital will be needed; future financing could dilute shareholders or impose debt or collaboration terms. The effective shelf registration permits offerings of up to $400M, and an at-the-market program permits up to $200M in stock sales; no ATM sales had occurred by the filing.
- ELVN-001 was in a Phase 1 trial in adults with CML; ELVN-002 was in a Phase 1 trial in adults with solid tumors with HER2 alterations. A third candidate was nominated in Q2 2023; no clinical trials had begun for other candidates.
- Key risks include clinical failure or delay, patient-enrollment challenges, regulatory uncertainty, competition, dependence on third-party research and manufacturing, and single-source supply exposure. The filing also cites macroeconomic and geopolitical uncertainty and potential disruption from public-health events. Management reported minor prior preclinical delays associated with a CRO, but no material business disruption or asset impairment from the cited macroeconomic and geopolitical developments to date.
- Facility lease payments totaled $423,000 through 2024. Vendor agreements may include cancellation or termination payments not separately quantified. No material litigation was pending; a merger-related shareholder action was voluntarily dismissed in January 2023, with an immaterial mootness fee paid. No dividends have been declared or paid.
- Management concluded disclosure controls were effective at a reasonable assurance level as of September 30, 2023; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- How the stated liquidity runway into early 2026 aligns with the separate estimate of at least 12 months from the filing date, considering planned trial spending and assumptions.
- Clinical-trial progress, safety, efficacy, enrollment and timing for ELVN-001 and ELVN-002, and the development plan for the third candidate.
- Quarterly cash burn and the pace of R&D and stock-based compensation growth relative to available liquidity.
- Potential dilution from outstanding options, future equity awards, the shelf registration and the unused $200M ATM program.
- Reliability and continuity of third-party manufacturing and CRO supply, including the disclosed single-source exposure.